| Citation: |
WANG Jing, ZHOU Bei, WU Zhong, WU Chenhao. Mechanism of microRNA-141 regulates epithelial-mesenchymal transition in breast cancer by targeting epidermal growth factor receptor[J]. Journal of Clinical Medicine in Practice, 2022, 26(19): 14-21. DOI: 10.7619/jcmp.20221276
|
To screen and investigate the expression levels of microRNA-141 (miR-141) and epidermal growth factor receptor (EGFR) in breast cancer cells and their effects on epithelial-mesenchymal transition, cell migration and invasion through bioinformatics.
Microarray analysis was used to screen differentially expressed genes; the weighted gene co-expression network analysis (WGCNA) and protein-protein interaction network of genes were used to identify key genes of breast cancer; the real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) was used to detect the expressions of miR-141 and EGFR in breast cancer tissues and cells; the Targetscan and Miranda were used to predict the target relationship between miR-141 and EGFR, and the target relationship between them was verified by dual luciferase reporter gene detection; the Transwell assay was used to evaluate migration ability of cells; the cell viability was detected by CCK-8 method; the western blot was used to detect the expressions of E-cadherin and vimentin.
The results of gene expression heat map and WGCNA analysis showed that EGFR was significantly highly expressed in tumor tissues. It was verified by molecular biology that the expression of miR-141 was significantly down-regulated and the expression of EGFR was significantly up-regulated in breast cancer tissues and cells (P < 0.05). Dual luciferase reporter gene detection found that EGFR was a target gene of miR-141, and was regulated by miR-141 expression in breast cancer cells. Cell experiments showed that the migration and proliferation of breast cancer cells were inhibited in miR-141 overexpression group, while the opposite results were observed in the EGFR group, and there were significant differences between two groups (P < 0.05). Overexpression of miR-141 was able to significantly promote the expression of E-cadherin and significantly inhibit the expression of Vimentin (P < 0.05), indicating that overexpression of miR-141 can inhibit the process of epithelial-mesenchymal transition of tumor cells.
The miR-141 can inhibit the proliferation of breast cancer cells and regulate progress of epithelial-mesenchymal transition by targeting EGFR.
| [1] |
甘霖, 王亚冬, 王婷, 等. miR-486-3p对乳腺癌细胞MCF-7凋亡的调控作用研究[J]. 中国细胞生物学学报, 2021, 43(9): 1776-1786. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZZ202109007.htm
|
| [2] |
王雪振, 夏雷. MiRNA-145在肿瘤表达中的生物学意义研究进展[J]. 重庆医学, 2021, 50(16): 2826-2830. doi: 10.3969/j.issn.1671-8348.2021.16.027
|
| [3] |
何姗姗, 骆建美, 刘贤, 等. miR-34、VEGF-C及sIL-2R检测在乳腺癌淋巴结转移中的预测[J]. 分子诊断与治疗杂志, 2021, 13(8): 1272-1275, 1280. doi: 10.3969/j.issn.1674-6929.2021.08.019
|
| [4] |
FARGHALY A M, ABOULWAFA O M, BAGHDADI H H, et al. New thieno[3, 2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells[J]. Bioorg Chem, 2021, 115: 105208. doi: 10.1016/j.bioorg.2021.105208
|
| [5] |
ZHU Y Y, ZHANG H, HAN X X, et al. STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells[J]. Cancer Lett, 2021, 519: 328-342. doi: 10.1016/j.canlet.2021.07.048
|
| [6] |
BALBUENA-REBOLLEDO Ι, PADILLA-MARTÍNEZ Ι Ι, ROSALES-HERNÍNDEZ M C, et al. Repurposing FDA drug compounds against breast cancer by targeting EGFR/HER2[J]. Pharmaceuticals (Basel), 2021, 14(8): 791. doi: 10.3390/ph14080791
|
| [7] |
邹敏, 孙奕琛, 刘文, 等. miRNA-10a及miRNA-27a在老年乳腺癌患者术后复发转移监测中的价值[J]. 中国老年学杂志, 2021, 41(15): 3180-3184. doi: 10.3969/j.issn.1005-9202.2021.15.010
|
| [8] |
MUSCELLA A, STEFÁNO E, CALABRISO N, et al. Role of epidermal growth factor receptor signaling in a Pt(Ⅱ)-resistant human breast cancer cell line[J]. Biochem Pharmacol, 2021, 192: 114702. doi: 10.1016/j.bcp.2021.114702
|
| [9] |
LEV S. Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis[J]. Biochem Soc Trans, 2020, 48(2): 657-665. doi: 10.1042/BST20191055
|
| [10] |
ANBUSELVAM M, EASWARAN M, MEYYAZHAGAN A, et al. Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer[J]. J Biomol Struct Dyn, 2021, 39(12): 4462-4471. doi: 10.1080/07391102.2020.1777899
|
| [11] |
AGNELLO L, TORTORELLA S, D′ARGENIO A, et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors[J]. J Exp Clin Cancer Res, 2021, 40(1): 239. doi: 10.1186/s13046-021-02039-w
|
| [12] |
蒋威华, 伊丽娜, 张晨光, 等. 三阴性乳腺癌中间质-上皮细胞转化因子及脂肪酸合成酶的表达情况及对预后的影响[J]. 实用临床医药杂志, 2021, 25(8): 16-20. doi: 10.7619/jcmp.20210355
|
| [13] |
CUI N P, QIAO S, JIANG S, et al. Protein tyrosine kinase 7 regulates EGFR/Akt signaling pathway and correlates with malignant progression in triple-negative breast cancer[J]. Front Oncol, 2021, 11: 699889. doi: 10.3389/fonc.2021.699889
|
| [14] |
VOUTILAINEN S, HEIKKILÄ P, SAMPO M, et al. Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact[J]. Acta Oncol, 2021, 60(9): 1233-1239. doi: 10.1080/0284186X.2021.1950927
|
| [15] |
张耀天, 韩翰. 间充质干细胞对乳腺癌细胞的影响[J]. 沈阳医学院学报, 2020, 22(2): 183-186. https://www.cnki.com.cn/Article/CJFDTOTAL-SYYX202002028.htm
|
| [16] |
ATEF M M, AMER A Ι, HAFEZ Y M, et al. Long non-coding RNA EGFR-AS1 in colorectal cancer: potential role in tumorigenesis and survival via miRNA-133b sponge and EGFR/STAT3 axis regulation[J]. Br J Biomed Sci, 2021, 78(3): 122-129. doi: 10.1080/09674845.2020.1853913
|
| [17] |
MA D, LIU H M, ZHAO P P, et al. Programing assembling/releasing multifunctional miRNA nanomedicine to treat prostate cancer[J]. ACS Appl Mater Interfaces, 2020, 12(8): 9032-9040. doi: 10.1021/acsami.9b21707
|
| [18] |
VIGO-MORALES P R, BORRERO-GARCIA L D, DEL MAR MALDONADO M, et al. Sensitization of anti-EGFR/HER2 targeted therapy resistance in breast cancer cells by MiRNA manipulation[J]. FASEB J, 2019, 33(S1): 647.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: